Nonpharmacological Methods for Children

October 7, 2021 updated by: Diler Yilmaz, Bandırma Onyedi Eylül University

Shotblocker or Cold Application; Which One is More Effective in Reducing the Pain Associated With the Intramuscular Injection in Children: A Randomized Controlled Trial

The study was designed as a randomized controlled experimental research with the purpose of determining the effect of the methods of cold application and Shotblocker on the pain and anxiety level of the children in reducing the pain associated with the intramuscular injection.

The hypotheses of the study:

Hypothesis 0. Shotblocker and the cold application to the injection site prior to the injection are not effective in reducing the pain associated with the intramuscular injection in children.

Hypothesis 1. Using ShotBlocker during the intramuscular injection reduces the pain and anxiety experienced by the child.

Hypothesis 2. Applying cold to the injection site prior to the intramuscular injection reduces the pain and anxiety experienced by the child.

This research was designed as a randomized controlled experimental study in a university hospital in Çorum.

The sample of the study comprised 150 children aged 7 to 12 years who were brought to the pediatric injection room in a university hospital and had intramuscular injection. The children were randomized into the Shotblocker (n=50), cold application (n=50) and control (n=50) groups. In addition to Wong-Baker Pain Scale and Child Anxiety Scale, the Child Information Form was used in the study to determine the introductory characteristics of the children and their family.

Study Overview

Detailed Description

The population of this study consisted of the children within the age range of 7-12 years who applied to the injection room in the pediatrics clinic of a university hospital between November 2017 and June 2018. On the other hand, the sample of this study consisted of 150 children who met the case-selection criteria and agreed to participate in the study.

In the Power analysis carried out based on the literature, the sample size of the study was determined as 150 with the confidence level of 90% (α=0.10). For 150 children, the power was β=0.20, 1-β=0.80 with α =.05. The approximate number of subjects was calculated as 50 per group with the Cohen's effect size of α = .05 and the confidence interval of 95%. The children in the sample were randomly assigned to the following groups: Cold application, Shotblocker, and control. In order to determine which case to include in which group, the numbers were randomly distributed to the 3 groups without repetition using a software. In the study, the sample size for each of the 3 groups, that is, cold application group (n=50), Shotblocker group (n=50), and control group (n=50) was determined as 50.

The intramuscular injection was carried out in the pediatric injection room of a university hospital. Before the intervention, the parents and children were met, they were informed about the study, and they were asked whether they would accept to participate in the study. The written and verbal consent were obtained from the parents and the children, respectively. In order to ensure reliability in the study results, the intramuscular injection was applied by the same nurse having at least 5 years of working experience throughout the study; and the pain behavior and anxiety levels of the children were evaluated by the same researcher. The parents were allowed to stay with their children during the intramuscular injection.

The following information was obtained from the children and parents who agreed to participate in the study using the Child Information Form: the socio-demographic characteristics of the children and parent, the previous history of IM injection, the previous history of being subject to a painful intervention, whether the child took an analgesic drug within the last 6 hours, the body mass index (BMI), etc. Prior to the intramuscular injection, the children's weight and height were measured and recorded. The same medicine (procaine penicilline) was administered to all children.

During the intramuscular injection, it was ensured that the environmental factors (temperature, light, noise, etc.), the injection site, and the antiseptic solution (70% alcohol) were standardized. The injection site was wiped using an antiseptic (batticon/chlorhexidine) cotton by gently pressing from center to periphery. It was ensured that the child was in the appropriate position, that is, in the prone position, with the toes facing inward. Prior to the injection, Shotblocker or the cold gel pad was introduced to the children in the experimental group and they were informed of how they would be used. Furthermore, the children and parents were informed about the Wong-Baker FACES® Pain Rating Scale and Children's Fear Scale (CFS) to be used in the study. The parents and children who volunteered to take part in the study were informed of the scale scoring. Which parent would take part in the study was left to the choice of parents to take participate. The CFS scale was evaluated preoperatively after receiving consent from the children and parents and completing the information form. The pain evaluation was made by the children, parents, and observers right after the procedure. When applying the scales, a particular attention was paid so that the children, parents and observers would not see each other's evaluation and not affect one another. Before the injection, the anxiety level was evaluated by the child, parent, and researcher using Children's Fear Scale (CFS). After the injection; the pain level was evaluated by the child, parent, and researcher using the Wong-Baker FACES® Pain Rating Scale, and the anxiety level was evaluated by the parent and researcher using Children's Fear Scale (CFS).

The data of the study was collected using the Child Information Form, the Wong-Baker FACES® Scale, and Children's Fear Scale.

Child Information Form: This form was prepared by the researcher to get information about the children selected for the sample. This form contains a total of 12 questions such as socio-demographic characteristics of the children, whether the child has a health problem that affects her/his perception of pain, the previous history of IM injection, injection duration, and whether the child has injection fear, etc.

Wong-Baker FACES® Scale (WB-FACES): In this scale, there are six faces representing the pain in an increasing order of intensity from zero to five from left to right. The leftmost face has a smile on it, representing "no pain"; whereas the rightmost face has a crying expression, representing "the most intense pain." As the score obtained from the scale increases, the pain tolerance decreases, and vice versa. In practice, the child is asked to choose the face that best expresses her/his feelings. In the application of the scale, it is explained to the child that each face belongs to a person, and the faces represent a happy person with no pain or a sad person feeling a little or too much pain.

Children's Fear Scale (CFS): The scale is used to measure the levels of fear and anxiety in children. The child is shown a picture of 5 facial expressions, each having a score between "0" and "4" points. This scale can be easily applied by both researchers and families to measure the fear and anxiety before and during the applications. In the scale, while "0" refers to "no fear and anxiety"; "4" refers to "the highest fear and anxiety".

The data obtained in this study was analyzed using IBM SPSS Statistics 22 (IBM SPSS, Turkey). The fitness of the parameters to normal distribution was evaluated by the Shapiro-Wilks test. In the evaluation of the data, in addition to the descriptive statistical methods (Mean, Standard deviation, Frequency), one-way analysis of variance (ANOVA) test was used for the comparisons of three or more groups with normal distribution and Tamhane's T2 for the paired comparisons. On the other hand, Chi-Square test was used for the comparison of the qualitative data. The statistical significance was set at p<0.05.

Permission was obtained from the clinical research ethics committee (29.07.16 / 2016-41) to implement the study, and from the relevant institution to carry out the study. Before starting the research, all the children and parents were informed of the purpose of the study, how the study would be carried out, and how the data of the study would be used; and then their verbal and written consent were obtained through the Voluntary Informed Consent Form. Furthermore, they were informed that they could quit the study at any time without giving any reason.

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Corum, Turkey, 19040
        • Hitit University- Hitit Medical Faculty Hospital Pediatrics Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria: Children

  • were in the age group of 7-12 years
  • due to IM injection (penicilline (procaine penicilline)

Exclusion Criteria:

  • had developmental retardation/disability
  • had communication difficulty
  • had no chronic disease
  • had a history of analgesic drug within the last 6 hours

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cold application group (Group 1)
In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
Experimental: Shotblocker group (Group 2)
The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
Experimental: Control Group (Group 3)
The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wong-Baker FACES® Scale
Time Frame: Through painful procedure completion, an average of 10 minutes
The WB-FACES was developed by Wong and Baker in 1981 and revised in 1983. The scale is used to diagnose pain in children aged 3-18 years. It consists of six facial expressions, each one representing an increasing degree of pain scored on a scale 0 to 5 from left to right (0 = very happy/no pain, 5 = the worst pain imaginable). The first face is a happy face representing "no pain" (0) while the last face is a crying face representing "the worst pain imaginable" (5). Higher scores indicate low pain tolerance. Participants are asked to choose the facial expression that best represents their pain
Through painful procedure completion, an average of 10 minutes
Children's Fear Scale
Time Frame: Through painful procedure completion, an average of 10 minutes
The CFS was developed to measure fear and anxiety in children. It consists of five facial expressions that represent a range from neutral (0) to extreme fear (4). Both researchers and family members can use the CFS to measure fear and anxiety in children before and during procedures
Through painful procedure completion, an average of 10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Selen OZAKAR AKÇA, PhD, RN, Associate Professor, Hitit University
  • Study Chair: Havva Nur PELTEK KENDİRCİ, PhD, MD, Associate Professor, Hitit University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2017

Primary Completion (Actual)

June 30, 2018

Study Completion (Actual)

December 20, 2018

Study Registration Dates

First Submitted

September 16, 2021

First Submitted That Met QC Criteria

September 27, 2021

First Posted (Actual)

October 7, 2021

Study Record Updates

Last Update Posted (Actual)

October 15, 2021

Last Update Submitted That Met QC Criteria

October 7, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BANU-D-YILMAZ-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Child

Clinical Trials on Cold application group

3
Subscribe